220 related articles for article (PubMed ID: 24403446)
41. Overexpression of Fn14 promotes androgen-independent prostate cancer progression through MMP-9 and correlates with poor treatment outcome.
Huang M; Narita S; Tsuchiya N; Ma Z; Numakura K; Obara T; Tsuruta H; Saito M; Inoue T; Horikawa Y; Satoh S; Habuchi T
Carcinogenesis; 2011 Nov; 32(11):1589-96. PubMed ID: 21828059
[TBL] [Abstract][Full Text] [Related]
42. CIB1 depletion impairs cell survival and tumor growth in triple-negative breast cancer.
Black JL; Harrell JC; Leisner TM; Fellmeth MJ; George SD; Reinhold D; Baker NM; Jones CD; Der CJ; Perou CM; Parise LV
Breast Cancer Res Treat; 2015 Jul; 152(2):337-46. PubMed ID: 26105795
[TBL] [Abstract][Full Text] [Related]
43. Notch4 Signaling Confers Susceptibility to TRAIL-Induced Apoptosis in Breast Cancer Cells.
Naik S; MacFarlane M; Sarin A
J Cell Biochem; 2015 Jul; 116(7):1371-80. PubMed ID: 25704336
[TBL] [Abstract][Full Text] [Related]
44. Triple negative breast cancer therapy with CDK1 siRNA delivered by cationic lipid assisted PEG-PLA nanoparticles.
Liu Y; Zhu YH; Mao CQ; Dou S; Shen S; Tan ZB; Wang J
J Control Release; 2014 Oct; 192():114-21. PubMed ID: 25016158
[TBL] [Abstract][Full Text] [Related]
45. miR-9 and miR-200 Regulate PDGFRβ-Mediated Endothelial Differentiation of Tumor Cells in Triple-Negative Breast Cancer.
D'Ippolito E; Plantamura I; Bongiovanni L; Casalini P; Baroni S; Piovan C; Orlandi R; Gualeni AV; Gloghini A; Rossini A; Cresta S; Tessari A; De Braud F; Di Leva G; Tripodo C; Iorio MV
Cancer Res; 2016 Sep; 76(18):5562-72. PubMed ID: 27402080
[TBL] [Abstract][Full Text] [Related]
46. FZD7 has a critical role in cell proliferation in triple negative breast cancer.
Yang L; Wu X; Wang Y; Zhang K; Wu J; Yuan YC; Deng X; Chen L; Kim CC; Lau S; Somlo G; Yen Y
Oncogene; 2011 Oct; 30(43):4437-46. PubMed ID: 21532620
[TBL] [Abstract][Full Text] [Related]
47. Overexpression of CDCA7 predicts poor prognosis and induces EZH2-mediated progression of triple-negative breast cancer.
Ye L; Li F; Song Y; Yu D; Xiong Z; Li Y; Shi T; Yuan Z; Lin C; Wu X; Ren L; Li X; Song L
Int J Cancer; 2018 Nov; 143(10):2602-2613. PubMed ID: 30151890
[TBL] [Abstract][Full Text] [Related]
48. Global characterization of signalling networks associated with tamoxifen resistance in breast cancer.
Browne BC; Hochgräfe F; Wu J; Millar EK; Barraclough J; Stone A; McCloy RA; Lee CS; Roberts C; Ali NA; Boulghourjian A; Schmich F; Linding R; Farrow L; Gee JM; Nicholson RI; O'Toole SA; Sutherland RL; Musgrove EA; Butt AJ; Daly RJ
FEBS J; 2013 Nov; 280(21):5237-57. PubMed ID: 23876235
[TBL] [Abstract][Full Text] [Related]
49. Selective, nontoxic CB(2) cannabinoid o-quinone with in vivo activity against triple-negative breast cancer.
Morales P; Blasco-Benito S; Andradas C; Gómez-Cañas M; Flores JM; Goya P; Fernández-Ruiz J; Sánchez C; Jagerovic N
J Med Chem; 2015 Mar; 58(5):2256-64. PubMed ID: 25671648
[TBL] [Abstract][Full Text] [Related]
50. In vitro effects of phenytoin and DAPT on MDA-MB-231 breast cancer cells.
Aktas CC; Zeybek ND; Piskin AK
Acta Biochim Biophys Sin (Shanghai); 2015 Sep; 47(9):680-6. PubMed ID: 26206582
[TBL] [Abstract][Full Text] [Related]
51. Dasatinib is synergistic with cetuximab and cisplatin in triple-negative breast cancer cells.
Kim EM; Mueller K; Gartner E; Boerner J
J Surg Res; 2013 Nov; 185(1):231-9. PubMed ID: 23899511
[TBL] [Abstract][Full Text] [Related]
52. Expression of bone morphogenetic protein-10 (BMP10) in human urothelial cancer of the bladder and its effects on the aggressiveness of bladder cancer cells in vitro.
Zhang N; Ye L; Wu L; Deng X; Yang Y; Jiang WG
Anticancer Res; 2013 May; 33(5):1917-25. PubMed ID: 23645739
[TBL] [Abstract][Full Text] [Related]
53. Raloxifene reduces triple-negative breast cancer tumor growth and decreases EGFR expression.
Taurin S; Allen KM; Scandlyn MJ; Rosengren RJ
Int J Oncol; 2013 Sep; 43(3):785-92. PubMed ID: 23842642
[TBL] [Abstract][Full Text] [Related]
54. IGFBP7 reduces breast tumor growth by induction of senescence and apoptosis pathways.
Benatar T; Yang W; Amemiya Y; Evdokimova V; Kahn H; Holloway C; Seth A
Breast Cancer Res Treat; 2012 Jun; 133(2):563-73. PubMed ID: 21997538
[TBL] [Abstract][Full Text] [Related]
55. Dual targeted therapy with p53 siRNA and Epigallocatechingallate in a triple negative breast cancer cell model.
Braicu C; Pileczki V; Pop L; Petric RC; Chira S; Pointiere E; Achimas-Cadariu P; Berindan-Neagoe I
PLoS One; 2015; 10(4):e0120936. PubMed ID: 25849487
[TBL] [Abstract][Full Text] [Related]
56. Knockdown of CAVEOLIN-1 Sensitizes Human Basal-Like Triple-Negative Breast Cancer Cells to Radiation.
Zou M; Li Y; Xia S; Chu Q; Xiao X; Qiu H; Chen Y; Zheng Z; Liu F; Zhuang L; Yu S
Cell Physiol Biochem; 2017; 44(2):778-791. PubMed ID: 29169152
[TBL] [Abstract][Full Text] [Related]
57. 1Alpha,25-dihydroxyvitamin D3 induces de novo E-cadherin expression in triple-negative breast cancer cells by CDH1-promoter demethylation.
Lopes N; Carvalho J; Durães C; Sousa B; Gomes M; Costa JL; Oliveira C; Paredes J; Schmitt F
Anticancer Res; 2012 Jan; 32(1):249-57. PubMed ID: 22213313
[TBL] [Abstract][Full Text] [Related]
58. Novel cell-penetrating peptide-loaded nanobubbles synergized with ultrasound irradiation enhance EGFR siRNA delivery for triple negative Breast cancer therapy.
Jing H; Cheng W; Li S; Wu B; Leng X; Xu S; Tian J
Colloids Surf B Biointerfaces; 2016 Oct; 146():387-95. PubMed ID: 27388967
[TBL] [Abstract][Full Text] [Related]
59. Lentiviral vector-mediated doxycycline-inducible USP39 shRNA or cDNA expression in triple-negative breast cancer cells.
Liu S; Liu X; Wang H; Zhou Q; Liang Y; Sui A; Yao R; Zhao B; Sun M
Oncol Rep; 2015 May; 33(5):2477-83. PubMed ID: 25812575
[TBL] [Abstract][Full Text] [Related]
60. Kit and PDGFR-alpha activities are necessary for Notch4/Int3-induced tumorigenesis.
Raafat A; Zoltan-Jones A; Strizzi L; Bargo S; Kimura K; Salomon D; Callahan R
Oncogene; 2007 Feb; 26(5):662-72. PubMed ID: 16878155
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
